



TERSANO BULLETIN ON THE CORONAVIRUS

Monday, April 20, 2020

We are writing to all of our customers and partners to provide our latest update regarding the status of the Tersano SAO™ solution pertaining to SARS-CoV-2 (Coronavirus) effectiveness claims.

In our most recent testing, the SAO solution was tested against an approved surrogate for SARS-CoV-2, which is the Coronavirus/MHV-3. MHV-3 (Murine coronavirus/Murine Hepatitis Virus) is one of the approved surrogates as it belongs to the same Genus (Betacoronavirus) as SARS (SARS-CoV), MERS (MERS-CoV) and COVID-19 (SARS-CoV-2). While testing against MHV-3, the lab also tested against Influenza A Virus (H1N1), Measles Virus and Syncytial Respiratory Virus.

We are pleased to announce that Tersano's SAO solution was effective in eliminating >99.99% (>4-log) of all four (4) enveloped viruses with a one minute dwell time. Please see our updated Pathogen Summary.

For our next stage of testing, we have been informed by various labs that they will soon begin offering efficacy testing against SARS-CoV-2, the causative agent of COVID-19. They are in the process of preparing virus stock, performing feasibility, and developing test protocols that are aligned with the requirements of the regulatory bodies. They plan to offer testing starting some time in June.

Please reach out with any questions or concerns to either myself or our partners around the world.

We wish you all the best of health.

A handwritten signature in blue ink, appearing to read "Steve Hengsperger".

Steve Hengsperger
President